12 Health Care Stocks Moving In Friday's Pre-Market Session
Craig-Hallum Maintains Biodesix(BDSX.US) With Buy Rating, Announces Target Price $3
Biodesix Analyst Ratings
Scotiabank Maintains Biodesix(BDSX.US) With Buy Rating, Cuts Target Price to $3
Scotiabank Initiates Biodesix at Sector Outperform With $3 Price Target
Biodesix to Present at Two Investor Conferences in September
Lake Street Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $3
Lake Street Sticks to Its Buy Rating for Biodesix (BDSX)
Biodesix Releases Updated Corporate Presentation Information
Biodesix Second Quarter 2024 Earnings: Beats Expectations
Express News | Biodesix Inc : TD Cowen Raises Target Price to $3 From $2.8
Buy Rating on Biodesix Affirmed Following Strong Q2 Performance and Positive Growth Indicators
Earnings Call Summary | Biodesix(BDSX.US) Q2 2024 Earnings Conference
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Express News | Biodesix Sees FY24 Revenue $70M-$72M Vs $66.98M Estimate
Biodesix | 10-Q: Q2 2024 Earnings Report
Biodesix GAAP EPS of -$0.08 Beats by $0.01, Revenue of $17.9M Beats by $1.76M
Earnings Flash (BDSX) BIODESIX Reports Q2 Revenue $17.9M, Vs. Street Est of $16.1M
Express News | Biodesix Inc - Raises Full-Year 2024 Revenue Guidance to $70-72 Mln From $65-68 Mln
Express News | Biodesix Q2 Revenue USD 17.9 Million Vs. IBES Estimate USD 16.2 Million